Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bi-weekly Cetuximab Combined With FOLFOX-6 in Metastatic Colorectal Cancer - CEBIFOX

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Universität Duisburg-Essen.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Universität Duisburg-Essen
ClinicalTrials.gov Identifier:
NCT01051167
First received: January 15, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted

January 15, 2010
January 15, 2010
February 2009
September 2011   (final data collection date for primary outcome measure)
Response rate (RECIST-Criteria) [ Time Frame: Every 8 weeks ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Secondary objectives: Safety, Quality of life [ Time Frame: Every 2 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Bi-weekly Cetuximab Combined With FOLFOX-6 in Metastatic Colorectal Cancer - CEBIFOX
Bi-weekly Cetuximab Combined With FOLFOX-6 as First-line Treatment in Metastatic Colorectal Cancer Patients With Wild-type K-ras Status

Cetuximab is normally given as a weekly schedule in the therapy of patients with metastatic colorectal cancer.

In order to improve the convenience for the patients in first line-therapy this study will evaluate the efficacy and safety of a bi-weekly combination of cetuximab with FOLFOX.

For years the effective treatment of advanced CRC was limited to 5-FU. Combination of 5-FU or a 5-FU analog with oxaliplatin, which has some antitumor activity as a single agent, shows synergistic activity. Combining oxaliplatin with a twice monthly folinic acid/5-FU schedule leads to a further improvement in first-line treatment of advanced CRC thus emerging to a standard regimen in first-line therapy of mCRC.

Cetuximab is normally given as a weekly schedule. As recently shown a biweekly schedule with 500 mg/m² instead of the weekly standard regimen (initial dose of 400 mg/m² followed by 250 mg/m² every week) exhibits similar pharmacokinetic results with a comparable efficacy.

In order to improve the convenience for the patients, this study will evaluate the efficacy and safety of a bi-weekly combination of cetuximab with FOLFOX. Out of the various FOLFOX regimens the most convenient FOLFOX-6 schedule is chosen for the study, which has been tested before in two studies in combination with the standard weekly schedule of cetuximab. Recent data suggest a decreased efficacy of cetuximab in patients bearing a k-ras mutation in their CRC. Therefore only patients with no evidence for a mutated k-ras gene in the colorectal carcinoma cells will be included in this study.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Colorectal Cancer
Drug: Cetuximab
500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
Other Name: Erbitux®
Experimental: Cetuximab + Folfox-6-regime

Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:

Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h.

Intervention: Drug: Cetuximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
59
September 2014
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically proven metastatic colorectal cancer
  • Molecular test showing no mutation in the k-ras gene of colorectal carcinoma cells
  • Male and female subjects ≥ 18 years of age
  • 1st occurrence of metastatic disease (not curatively resectable)
  • Life expectancy ≥ 12 weeks
  • Presence of at least 1 bi-dimensionally measurable index lesion (not in an irradiated area)
  • ECOG performance status ≤ 2 at study entry
  • Adequate bone marrow reserve:

leucocytes ≥ 3.0 x 109/l with neutrophils ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, haemoglobin ≥ 6.21 mmol/l (10 g/dl)

  • ASAT and ALAT ≤ 2.5 x upper reference range, in case of liver metastasis ≤ 5 x upper reference range
  • Serum creatinine ≤ 1.5 x upper reference range
  • Bilirubin ≤ 1.5 x upper reference range
  • Negative pregnancy test for female and effective contraception for both male and female subjects if the risk of conception exists
  • Signed written informed consent

Exclusion Criteria:

  • Evidence for a mutation of the k-ras gene in the colorectal carcinoma cells
  • Previous exposure to epidermal growth factor receptor-targeting therapy
  • Prior chemotherapy for metastatic disease
  • Prior oxaliplatin based adjuvant chemotherapy or < 6 months after end of adjuvant treatment
  • Other previous malignancy with exception of a history of a previous curatively treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
  • Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before registration
  • Concurrent chronic systemic immune therapy or hormone therapy not indicated in this study protocol
  • Creatinine clearance < 30 ml/min
  • Known hypersensitivity reaction to any of the components of study treatment
  • Pregnancy (absence to be confirmed by ß-hCG test) or lactation period
  • Clinically relevant coronary artery disease, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
  • Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
  • Brain metastasis (known or suspected)
  • Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent
  • Known alcohol or drug abuse
  • Participation in another clinical study within the 30 days before registration
  • Peripheral neuropathy > grade 1
  • Significant disease which, in the investigator's opinion, would exclude the patient from the study
  • Legal incapacity or limited legal capacity
Both
18 Years and older
No
Contact: Tanja Trarbach, MD +49(0)2 01 / 7233449 tanja.trarbach@uk-essen.de
Germany
 
NCT01051167
TT1-2007, 2007-000460-24
No
Tanja Trarbach, MD, University of Duisburg-Essen, Medical School
Universität Duisburg-Essen
Not Provided
Principal Investigator: Tanja Trarbach, MD University of Duisburg-Essen Medical School
Universität Duisburg-Essen
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP